| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FBP; FOLR |
| Entrez GeneID | 2348 |
| clone | 3G12B7 |
| WB Predicted band size | 29.8kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human FOLR1 (AA: 41-227) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于FOLR1抗体的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Folate Receptor Alpha as a Therapeutic Target in Ovarian Cancer"*
**作者**: K. Kalli et al.
**摘要**: 该研究探讨了FOLR1(叶酸受体α)在卵巢癌中的过表达及其作为治疗靶点的潜力，评估了抗FOLR1抗体药物偶联物(如Mirvetuximab)的临床前和临床试验结果，证明其在FOLR1高表达肿瘤中的有效性。
2. **文献名称**: *"Development of a Novel Anti-FOLR1 Antibody for Targeted Therapy in Triple-Negative Breast Cancer"*
**作者**: J. Zhang et al.
**摘要**: 研究团队开发了一种新型抗FOLR1单克隆抗体，通过体外和体内实验验证其特异性结合能力，并证明其可抑制三阴性乳腺癌细胞增殖，为FOLR1靶向治疗提供了新策略。
3. **文献名称**: *"Immunohistochemical Detection of Folate Receptor Alpha in Lung Adenocarcinomas"*
**作者**: M. Nunez et al.
**摘要**: 该文献系统评估了FOLR1抗体在肺腺癌组织中的免疫组化检测效能，发现FOLR1高表达与患者预后不良相关，提示其可作为诊断标志物和潜在治疗靶点。
---
**注**：以上文献为示例，实际引用时需核对具体来源(如PubMed ID或期刊卷期)。如需进一步扩展，可补充特定抗体类型(如单抗、双抗)或应用场景(如成像、药物递送)的研究。
**Background of FOLR1 Antibodies**
Folate receptor alpha (FOLR1), a glycosylphosphatidylinositol (GPI)-anchored membrane protein, facilitates cellular uptake of folate and its derivatives by mediating receptor-mediated endocytosis. FOLR1 is overexpressed in various malignancies, including ovarian, endometrial, lung, and breast cancers, while exhibiting limited expression in normal tissues. This tumor-selective expression makes FOLR1 a promising therapeutic and diagnostic target.
FOLR1-targeting antibodies are engineered to exploit this specificity. Therapeutically, they are utilized in antibody-drug conjugates (ADCs) or bispecific antibodies to deliver cytotoxic payloads or engage immune cells directly at tumor sites. For example, mirvetuximab soravtansine, an FOLR1-directed ADC, has shown efficacy in platinum-resistant ovarian cancer. Diagnostically, FOLR1 antibodies aid in immunohistochemical detection of FOLR1 expression to guide treatment eligibility.
Research highlights FOLR1's role in cancer progression, including folate metabolism dysregulation and potential resistance to conventional therapies. However, challenges like heterogeneous FOLR1 expression across tumors and on-target toxicity in folate-rich tissues (e.g., kidneys) necessitate optimized antibody designs. Current studies focus on improving tumor penetration, reducing immunogenicity, and combining FOLR1-targeted therapies with checkpoint inhibitors or chemotherapy. These efforts aim to expand clinical applications and overcome resistance mechanisms in FOLR1-positive cancers.
×
